Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focusing on central nervous system (CNS) disorders, has announced its participation in two upcoming investor conferences. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 12:00pm EDT in New York, NY. Additionally, Praxis will attend the Baird Global Healthcare Conference on September 11, 2024, at 2:35pm EDT, also in New York, NY.
Both presentations will be in a fireside chat format. The company will be available for one-on-one meetings with interested investors during these conferences. A replay of the presentations will be available on Praxis' website for 90 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PRAX declined 2.75%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be attending and presenting at two upcoming conferences:
H.C. Wainwright 26th Annual Global Investment Conference
Format: Fireside Chat
Presentation date and time: September 9, 2024 at 12:00pm EDT
Location: Lotte New York Palace Hotel, New York, NY
Webcast: here
Baird Global Healthcare Conference
Format: Fireside Chat
Presentation date and time: September 11, 2024 at 2:35pm EDT
Location: InterContinental Barclay Hotel, New York, NY
The Company will be available for one-on-one meetings during these conferences. Interested investors should contact their respective H.C. Wainwright and/or Baird representatives to request meetings. A replay of the presentation will be posted, when available, to Praxis’ website on the “Events and Presentations” page under the investor section of the website for 90 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When and where is Praxis Precision Medicines (PRAX) presenting at the H.C. Wainwright conference?
What is the format of Praxis Precision Medicines' (PRAX) presentations at the upcoming investor conferences?
How long will the replay of Praxis Precision Medicines' (PRAX) presentations be available on their website?
What type of disorders does Praxis Precision Medicines (PRAX) focus on in their drug development?
How can investors arrange meetings with Praxis Precision Medicines (PRAX) during the conferences?
